{"id":"placebo-piroxicam","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Gastrointestinal upset (dyspepsia, nausea)"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Dizziness"},{"rate":"2-5","effect":"Rash"},{"rate":"1-2","effect":"Gastrointestinal bleeding"}]},"_chembl":{"chemblId":"CHEMBL527","moleculeType":"Small molecule","molecularWeight":"331.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piroxicam non-selectively inhibits both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By blocking prostaglandin synthesis, piroxicam reduces inflammatory responses and provides analgesic and antipyretic effects. It is a long-acting NSAID with a prolonged half-life, allowing for once-daily dosing.","oneSentence":"Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:19.515Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Acute musculoskeletal pain and inflammation"}]},"trialDetails":[{"nctId":"NCT07449299","phase":"PHASE3","title":"Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2027-03","conditions":"Emergency Contraception, Contraception, COX-2 Inhibitor","enrollment":1458},{"nctId":"NCT06727734","phase":"PHASE3","title":"Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-12","conditions":"Contraception","enrollment":980},{"nctId":"NCT06404177","phase":"PHASE3","title":"Enantyum® IV Versus Piroxen® IM in Emergency Pain Management","status":"RECRUITING","sponsor":"Riadh Boukef","startDate":"2023-07-15","conditions":"Traumatic Injury","enrollment":300},{"nctId":"NCT03614494","phase":"PHASE2, PHASE3","title":"Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception","status":"COMPLETED","sponsor":"Dr. Hang Wun Raymond Li","startDate":"2018-08-20","conditions":"Emergency Contraception","enrollment":860},{"nctId":"NCT02304783","phase":"PHASE3","title":"Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2014-01","conditions":"Renal Colic","enrollment":1400},{"nctId":"NCT05722782","phase":"PHASE2","title":"Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics","status":"RECRUITING","sponsor":"University of Monastir","startDate":"2023-07-01","conditions":"Renal Colic","enrollment":500},{"nctId":"NCT04062591","phase":"EARLY_PHASE1","title":"Efficacy of Piroxicam as a Perioperative Analgesic for Patients Undergoing Fixation of Maxillofacial Fractures","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-08-16","conditions":"Postoperative Pain","enrollment":72},{"nctId":"NCT03998826","phase":"NA","title":"Piroxicam Premedication for Postendodontic Pain in Non-vital Mandibular Molars","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-09-01","conditions":"Non-Vital Tooth","enrollment":60},{"nctId":"NCT03153657","phase":"PHASE3","title":"Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching","status":"COMPLETED","sponsor":"Universidade Federal de Sergipe","startDate":"2016-12-13","conditions":"Tooth Sensitivity, Toothache","enrollment":50},{"nctId":"NCT01320709","phase":"PHASE2","title":"Effect of Piroxicam on Ovulation","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-03","conditions":"Contraception, Postcoital","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo - Piroxicam","genericName":"Placebo - Piroxicam","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute musculoskeletal pain and inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}